Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation
Findings from a pre-specified translational analysis of the MITO END-3 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who Relapse Within 12 Months of Standard-of-Care Chemotherapy or Surgery for Early TNBC
Overall survival results from the IMpassion132 study
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Follicular Lymphoma
Evidence for efficacy is based on the results from the TRANSCEND-FL study
Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient mCRC Treated with ICIs Surpass the Benefit Observed in dMMR/MSI-H mCRC
Findings from a global study in patients with mCRC harbouring POLE/D1 mutations
EMA Recommends Granting a Marketing Authorisation for Generic Eribulin
Eribulin Baxter is a generic of Halaven, which has been authorised in the EU since 2011
Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced HCC Who Were Sorafenib Intolerant or Refractory
5-year results from the CheckMate 040 study
Adding 24 Months of ADT Improves Metastasis-Free Survival in Patients with Prostate Cancer Treated with Postoperative Radiotherapy
Findings from the RADICALS-HD study
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell Lung Cancer
Evidence for efficacy is based on the results from the DeLLphi-301 study
Neoadjuvant Dabrafenib Plus Trametinib Has High Pathological Response Rates in Clinical Stage III Melanoma, But Low Rates of Recurrence-Free Survival
Updated analysis of the phase II NeoCombi study
EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of Resected ALK-positive NSCLC
New indication concerns adjuvant treatment for ALK-positive NSCLC at high risk of recurrence
Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than Chemotherapy in Patients with Resectable NSCLC
Findings from the CheckMate 77T study
Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal Junction Cancer Treated with Trastuzumab Deruxtecan
Findings from the exploratory biomarker analyses of the DESTINY-Gastric01 study